Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Combined Automated Blood Tests Estimate Prostate Cancer Probability

By LabMedica International staff writers
Posted on 19 Apr 2010
Three automated blood tests combined into one index estimates a man's probability of having prostate cancer found on biopsy.

A new prostate disease marker, p2prostate-specific antigen (p2PSA), and the Prostate Health Index (phi), significantly improve the specificity of prostate cancer biomarker assessment. More...


Serum Beckman Coulter (Nyon, Switzerland) phi is a multivariate index incorporating prostate-specific antigen (PSA), free PSA, and proPSA concentrations into a single result. This enables medical professionals to estimate the probability of cancer in men aged 50 and older with total PSA in the 2.0-10.0 ng/mL range and a nonsuspicious digital rectal examination (DRE).

proPSA is a novel serum marker strongly associated with prostate cancer and delivers added specificity to PSA. As a result, phi contributes to reduce significantly the number of negative biopsies resulting from suspicious PSA or free PSA results.

Beckman Coulter phi is a composite score of Access Hybritech PSA, free PSA and the new p2PSA assay, which measures the isoform proPSA.

A new website introduced by Beckman Coulter, was designed to encourage dialogue between patients, physicians, and laboratory professionals. It provides guidance and education to all parties in order to foster confident prostate biopsy decision-making. The website (please see related links below) provides links to credible medical resources, the latest unbiased scientific studies, and details the benefits of the latest blood test, which can noninvasively identify patients who are most likely to have a negative prostate biopsy.

Related Links:

Beckman Coulter

Prostate Health Index



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.